GSK’s 5-in-1 meningococcal vaccine, Penmenvy, is designed to protect people ages 10 to 25 against meningococcal serogroups A, B, C, W and Y (MenABCWY), which together cause the most persistent meningococcal disease (IMD) cases globally.
With this approval, GSK adds another option to its market-leading meningitis vaccine portfolio.
Prior to GSKs approval, Pfizer had a two-year run with the only 5-in-1 meningococcal vaccine in the US.
Click here to read the entire article.